The biology, pathology and therapeutic use of prostaglandins in the eye

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Prostaglandins (PGs) are ubiquitous compounds found throughout the body, including the eye. They are involved in a variety of ocular functions, two of which are intraocular pressure (IOP) regulation and mediation of inflammation. Currently, PG analogs are the mainstay of topical IOP lowering therapy for glaucoma. The IOP effects of PGs are mediated by their actions on matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases, thereby facilitating the outflow of aqueous humor from the eye. Clinically used PGs are PGF analogs which bind to PGF receptors to influence matrix metalloproteinase transcription through c-Fos and c-Jun. Biological antagonists of endogenous PGs, including steroids and nonsteroidal anti-inflammatory drugs, are commonly used for control of ocular inflammation and management of cystoid macular edema. Recent work has demonstrated that endogenous PGs are implicated in the pathogenesis of diabetic retinopathy, macular degeneration and carcinogenesis.

Original languageEnglish (US)
Pages (from-to)577-591
Number of pages15
JournalClinical Lipidology
Volume6
Issue number5
DOIs
StatePublished - Oct 1 2011

Fingerprint

Therapeutic Uses
Prostaglandins
Intraocular Pressure
Pathology
Matrix Metalloproteinases
Inflammation
Synthetic Prostaglandins
Tissue Inhibitor of Metalloproteinases
Prostaglandin Antagonists
Matrix Metalloproteinase Inhibitors
Macular Edema
Aqueous Humor
Macular Degeneration
Prostaglandins F
Diabetic Retinopathy
Glaucoma
Carcinogenesis
Anti-Inflammatory Agents
Steroids
Pharmaceutical Preparations

Keywords

  • aqueous humor outflow
  • arachidonic acid
  • cyclooxygenases
  • glaucoma
  • inflammation
  • intraocular pressure
  • prostaglandin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

The biology, pathology and therapeutic use of prostaglandins in the eye. / Toris, Carol B; Gulati, Vikas.

In: Clinical Lipidology, Vol. 6, No. 5, 01.10.2011, p. 577-591.

Research output: Contribution to journalReview article

@article{99c4b764b3e04a7bbd88ecd89d67c639,
title = "The biology, pathology and therapeutic use of prostaglandins in the eye",
abstract = "Prostaglandins (PGs) are ubiquitous compounds found throughout the body, including the eye. They are involved in a variety of ocular functions, two of which are intraocular pressure (IOP) regulation and mediation of inflammation. Currently, PG analogs are the mainstay of topical IOP lowering therapy for glaucoma. The IOP effects of PGs are mediated by their actions on matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases, thereby facilitating the outflow of aqueous humor from the eye. Clinically used PGs are PGF 2α analogs which bind to PGF receptors to influence matrix metalloproteinase transcription through c-Fos and c-Jun. Biological antagonists of endogenous PGs, including steroids and nonsteroidal anti-inflammatory drugs, are commonly used for control of ocular inflammation and management of cystoid macular edema. Recent work has demonstrated that endogenous PGs are implicated in the pathogenesis of diabetic retinopathy, macular degeneration and carcinogenesis.",
keywords = "aqueous humor outflow, arachidonic acid, cyclooxygenases, glaucoma, inflammation, intraocular pressure, prostaglandin",
author = "Toris, {Carol B} and Vikas Gulati",
year = "2011",
month = "10",
day = "1",
doi = "10.2217/clp.11.42",
language = "English (US)",
volume = "6",
pages = "577--591",
journal = "Future Lipidology",
issn = "1758-4299",
publisher = "Future Medicine Ltd.",
number = "5",

}

TY - JOUR

T1 - The biology, pathology and therapeutic use of prostaglandins in the eye

AU - Toris, Carol B

AU - Gulati, Vikas

PY - 2011/10/1

Y1 - 2011/10/1

N2 - Prostaglandins (PGs) are ubiquitous compounds found throughout the body, including the eye. They are involved in a variety of ocular functions, two of which are intraocular pressure (IOP) regulation and mediation of inflammation. Currently, PG analogs are the mainstay of topical IOP lowering therapy for glaucoma. The IOP effects of PGs are mediated by their actions on matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases, thereby facilitating the outflow of aqueous humor from the eye. Clinically used PGs are PGF 2α analogs which bind to PGF receptors to influence matrix metalloproteinase transcription through c-Fos and c-Jun. Biological antagonists of endogenous PGs, including steroids and nonsteroidal anti-inflammatory drugs, are commonly used for control of ocular inflammation and management of cystoid macular edema. Recent work has demonstrated that endogenous PGs are implicated in the pathogenesis of diabetic retinopathy, macular degeneration and carcinogenesis.

AB - Prostaglandins (PGs) are ubiquitous compounds found throughout the body, including the eye. They are involved in a variety of ocular functions, two of which are intraocular pressure (IOP) regulation and mediation of inflammation. Currently, PG analogs are the mainstay of topical IOP lowering therapy for glaucoma. The IOP effects of PGs are mediated by their actions on matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases, thereby facilitating the outflow of aqueous humor from the eye. Clinically used PGs are PGF 2α analogs which bind to PGF receptors to influence matrix metalloproteinase transcription through c-Fos and c-Jun. Biological antagonists of endogenous PGs, including steroids and nonsteroidal anti-inflammatory drugs, are commonly used for control of ocular inflammation and management of cystoid macular edema. Recent work has demonstrated that endogenous PGs are implicated in the pathogenesis of diabetic retinopathy, macular degeneration and carcinogenesis.

KW - aqueous humor outflow

KW - arachidonic acid

KW - cyclooxygenases

KW - glaucoma

KW - inflammation

KW - intraocular pressure

KW - prostaglandin

UR - http://www.scopus.com/inward/record.url?scp=80054846753&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054846753&partnerID=8YFLogxK

U2 - 10.2217/clp.11.42

DO - 10.2217/clp.11.42

M3 - Review article

VL - 6

SP - 577

EP - 591

JO - Future Lipidology

JF - Future Lipidology

SN - 1758-4299

IS - 5

ER -